Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (76)

III-01Angela Äbelö

Population concentration-QT-modelling of CHF6001 following dry powder inhalation in healthy volunteers.

Thursday 09:55-11:30

III-02Nada Abla Geiser

Development of PBPK drug models to support antimalarial combination strategy

Thursday 09:55-11:30

III-03Amais Ahmad

Evaluation of Prediction Performance of In Silico PBPK models of oral drug absorption

Thursday 09:55-11:30

III-04Jae Eun Ahn

Pharmacokinetic/Pharmacodynamic effects of PF-06648671, a novel gamma secretase modulator following single and multiple dose administration in healthy volunteers

Thursday 09:55-11:30

III-05Yasunori Aoki

Second order Taylor expansion of likelihood-based models for fast covariate and random effect model building

Thursday 09:55-11:30

III-06Usman Arshad

Development of visual predictive checks accounting for multimodal parameter distributions in mixture models

Thursday 09:55-11:30

III-07Muhammad Waqar Ashraf

A semi-PBPK model to describe the mechanism based drug-drug interaction between S-ketamine and ticlopidine in healthy human volunteers.

Thursday 09:55-11:30

III-08Magnus Åstrand

Longitudinal pharmacometric modelling of serum potassium lowering effect of sodium zirconium cyclosilicate in patients with hyperkalemia

Thursday 09:55-11:30

III-09Linda Aulin

Quantitative modelling of procalcitonin as a treatment response biomarker in sepsis

Thursday 09:55-11:30

III-10Geraldine Celliere

Development of guidelines to efficiently choose and diagnose target-mediated drug disposition models

Thursday 09:55-11:30

III-11Vanessa Baier

Developing a physiology-based model of bile acid metabolism in men

Thursday 09:55-11:30

III-12Pavel Balazki

A Physiologically-based Quantitative Systems Pharmacology model of the incretin hormones GLP-1 and GIP

Thursday 09:55-11:30

III-13Belén Pérez Solans

Mechanistic model of the myeloablative effects of treosulfan and busulfan in pediatric patients undergoing bone marrow transplant

Thursday 09:55-11:30

III-14Irina Baltcheva

Model-based dose selection for the Phase 2b study of ianalumab in primary Sjögren’s Syndrome

Thursday 09:55-11:30

III-15Guillaume Baneyx

Target-mediated drug disposition modeling of lacnotuzumab in healthy volunteers and patients with advanced malignancies and triple negative breast cancer.

Thursday 09:55-11:30

III-16

Modelling waist-hip ratio increase in HIV-infected individuals starting antiretroviral therapy

Thursday 09:55-11:30

III-17Christian Bartels

ggPMX: a toolbox to easily generate a comprehensive set of model diagnostic plots for population models

Thursday 09:55-11:30

III-18Roberta Bartolucci

A PBPK model for the study of Azathioprine pharmacokinetics in rats and prediction in humans

Thursday 09:55-11:30

III-19Carla Bastida Fernández

PK/PD of the individual components of composite indexes variables used for disease activity assessment in rheumatoid arthritis patients on tocilizumab treatment.

Thursday 09:55-11:30

III-20Ryan Beechinor

A population pharmacokinetic study of high dose methotrexate treatment in infants with acute lymphoblastic leukemia: The importance of modeling inter-occasion variability across treatment cycles

Thursday 09:55-11:30

III-21Amina Bensalem

Concentration-effect relationships of therapeutic monoclonal antibody rituximab in rheumatoid arthritis.

Thursday 09:55-11:30

III-22Agathe Béranger

Piperacillin dosing regimen optimization in critically ill children according to different creatinine clearances

Thursday 09:55-11:30

III-23Agnieszka Bienert

Pharmacokinetics of dexmedetomidine in elderly patients undergoing sedation after abdominal aortic surgery.

Thursday 09:55-11:30

III-24Robert Bies

Pharmacokinetic-pharmacodynamic modelling of MK-2048 in ex vivo cervical tissue

Thursday 09:55-11:30

III-25Henrik Bjugård Nyberg

A pediatric population pharmacokinetic model for ethionamide in South African children treated for drug-susceptible or drug-resistant tuberculosis.

Thursday 09:55-11:30

III-26Alessandro Boianelli

A quantitative systems pharmacology model for understanding the role of dietary fructose metabolism in NAFLD

Thursday 09:55-11:30

III-27Charlotte Bon

Capacity limits of ASGPR mediated liver targeting

Thursday 09:55-11:30

III-28Rolien Bosch

A novel integrated QSP model of in vivo human glucose regulation to support development of a glucagon/GLP-1 dual agonist.

Thursday 09:55-11:30

III-29

Characterization of anti-drug antibodies using a bivariate mixed hidden Markov model

Thursday 09:55-11:30

III-30Philippine Eloy

Genetics of nevirapine and anti-tuberculosis drugs pharmacokinetics interaction in HIV-tuberculosis co-infected patients in Mozambique

Thursday 09:55-11:30

III-31Hannah Britz

Physiologically-based pharmacokinetic (PBPK) modeling of the strong CYP1A2 inhibitor fluvoxamine

Thursday 09:55-11:30

III-32Astrid Broeker

An integrated pharmacometric dialysis model to evaluate the pharmacokinetic impact of renal replacement therapy

Thursday 09:55-11:30

III-33Jantine Brussee

Dose Individualization of CYP3A Substrates in Children: Characterization of Maturation of Intestinal and Hepatic CYP3A Activity in Children to Predict First-pass and Systemic CYP3A-mediated Metabolism

Thursday 09:55-11:30

III-34Thierry Buclin

Closed-loop control for propofol administration during anesthesia based on real-time concentration measurement: a simulation study

Thursday 09:55-11:30

III-35Wonkyung Byon

Apixaban for treatment of venous thromboembolism (VTEtx): Use of Model-Based Meta-Analysis (MBMA) to support Phase 3 dose selection and beyond

Thursday 09:55-11:30

III-36Tim Cardilin

Modeling of radiation therapy and radiosensitizing agents in tumor xenografts

Thursday 09:55-11:30

III-37Evelina Cardoso

Population pharmacokinetic analysis of erlotinib in cancer patients affected by NSCLC

Thursday 09:55-11:30

III-38Marc Cerou

HAM-D score analysis of patients under placebo with major depressive disorder using item response theory

Thursday 09:55-11:30

III-39Blesson Chacko

Covariate effects on competing events: a simulation study comparing approaches

Thursday 09:55-11:30

III-40Dong Woo Chae

Predictive Modeling of PCA Effect on Postoperative Pain Management

Thursday 09:55-11:30

III-41Anne Chain

Extension of population pharmacokinetic analysis of pembrolizumab to paediatric patients patients with classical Hodgkin lymphoma

Thursday 09:55-11:30

III-42Pascal Chanu

Pediatric plans optimization of C.E.R.A. (Continuous Erythropoietin Receptor Activator): clinical evidence obtained through a model-based integration of multisource data

Thursday 09:55-11:30

III-43Estelle Chasseloup

Generation and Application of Avatars (Digital Twins) in Pharmacometric Modelling

Thursday 09:55-11:30

III-44Jonathan Chauvin

COSSAC (COnditional Sampling use for Stepwise Approach based on Correlation tests) method for covariate search

Thursday 09:55-11:30

III-45Chee Ng

Novel Multilevel Parallel Expectation Maximization (MPEM) Estimation Methods for Population Quantitative Pharmacology Analysis

Thursday 09:55-11:30

III-46Wenjun Chen

Modeling the antitumor efficacy and pharmacokinetic/pharmacodynamic interaction between docetaxel and cabozantinib in human prostate cancer xenograft mouse models

Thursday 09:55-11:30

III-47Mohammed Cherkaoui Rbati

A Liver Model for Chemoprotection Against Malaria

Thursday 09:55-11:30

III-48Manoranjenni Chetty

Antidepressants, anxiolytics and statins: prediction of exposure changes due to aging

Thursday 09:55-11:30

III-49S. Y. Amy Cheung

Challenges and opportunities in the development of medical therapies for paediatric populations and the role of extrapolation

Thursday 09:55-11:30

III-50Maxwell Chirehwa

Correlates of tuberculosis treatment outcomes: application of regression trees and pharmacodynamic modelling techniques

Thursday 09:55-11:30

III-51Jason Chittenden

PMDatR: A Pharmacometric Data Manipulation Package for R

Thursday 09:55-11:30

III-52Young-Kyung Choi

Population pharmacokinetics of cycloserine in patients with multidrug-resistant tuberculosis

Thursday 09:55-11:30

III-53Francois Combes

Modeling and Simulation Approach of Everolimus PK/PD Toward Completing a Pediatric Development

Thursday 09:55-11:30

III-54Valerie Cosson

Population PKPD modeling of RO7046015 (PRX002/RG7935), an Anti--Synuclein Monoclonal Antibody for the treatment of Parkinson’s Disease

Thursday 09:55-11:30

III-55Perrine Courlet

Comparison of escitalopram pharmacokinetics in HIV infected individuals with an uninfected psychiatric cohort

Thursday 09:55-11:30

III-56Vincent Croixmarie

Use of a multivariate distribution to simulate severe renal impaired patients

Thursday 09:55-11:30

III-57Ailing Cui

Quantitative Predictive Models for the Degree of Disability After Acute Ischemic Stroke

Thursday 09:55-11:30

III-59André Dallmann

Characterization of paracetamol hepatotoxicity during pregnancy through physiologically-based pharmacokinetic modeling

Thursday 09:55-11:30

III-60Daniel Kaschek

An Integrated R-Based Framework for Model Development in Health Economics

Thursday 09:55-11:30

III-61Kim Dao

Evaluation of exposure to vancomycin in neonates under existing dosing regimens using a population pharmacokinetic approach

Thursday 09:55-11:30

III-62Olivier David

A PKPD model describing the amyloid precursor protein (APP) derived peptides in subjects receiving CNP520, a BACE-1 inhibitor.

Thursday 09:55-11:30

III-63Nico de Jager

Population pharmacokinetic modelling of factor VIII levels during perioperative dosing of Haemate® P (Humate P) in patients diagnosed with von Willebrands Disease.

Thursday 09:55-11:30

III-64Giuseppe De Nicolao

Analysis of muscular biopsy distributional data in Duchenne Muscular Dystrophy treatment: a population approach

Thursday 09:55-11:30

III-65Mailys De Sousa Mendes

Mechanistic modelling of in-vitro bidirectional permeability studies and in vivo absorption of metoprolol

Thursday 09:55-11:30

III-66Elien De Thaye

In vitro data supporting circulating CCCK18 as potential pharmacodynamic biomarker in ovarian cancer

Thursday 09:55-11:30

III-67Aurelia de Vries Schultink

Therapeutic drug monitoring of endoxifen in ER-positive breast cancer patients: comparing data from clinical practice to model-based predictions.

Thursday 09:55-11:30

III-68

A Mechanistic Cellular Disposition Model of Bile Acid Handling in Sandwich-Cultured Human Hepatocytes

Thursday 09:55-11:30

III-69Oleg Demin

Simulations of tau-targeted therapies using quantitative systems pharmacology model of tau pathology

Thursday 09:55-11:30

III-70Oleg Demin Jr

Quantitative Systems Pharmacology Modeling of CAR-T Therapy and T Cell Engaging Bispecific Antibodies: B-cell Acute Lymphoblastic Leukemia Case Study

Thursday 09:55-11:30

III-71Aris Dokoumetzidis

Population pharmacokinetics of teicoplanin in preterm and term neonates with late-onset sepsis

Thursday 09:55-11:30

III-72Artem Dolgun

A functional, integrative R environment workflow for the development and use of quantitative systems pharmacology models

Thursday 09:55-11:30

III-73Anne-Gaelle Dosne

Optimizing Biomarker-Based Dosing Algorithm for Erdafitinib through PK-PD Modeling and Simulations

Thursday 09:55-11:30

III-74Erwin Dreesen

Development of a population pharmacokinetic and pharmacodynamic model to describe the effect of infliximab induction therapy on mucosal healing in patients with ulcerative colitis

Thursday 09:55-11:30

III-75Vincent Dubois

Comparative attributes of a semimechanistic and an empirical population PK model for durvalumab, a fully human anti-PD-L1 monoclonal antibody

Thursday 09:55-11:30

III-76Miro Eigenmann

Dynamic in vitro PKPD assessment to improve pharmacological response profiling of T-cell bispecifics

Thursday 09:55-11:30

III-77Salvatore D'Agate

Development of a drug-disease model describing individual IPSS trajectories in BPH patients: Implication of disease progression and covariate factors on long term treatment response

Thursday 09:55-11:30